share_log

Vaccinex Expects Topline Data For Phase 1/2a Randomized SIGNAL-AD Study Of Pepinemab For Alzheimer's Disease In Q3 2024

Benzinga ·  Apr 2 20:45
Vaccinex Expects Topline Data For Phase 1/2a Randomized SIGNAL-AD Study Of Pepinemab For Alzheimer's Disease In Q3 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment